4 Doses a Year, After 2 Starter Doses
Watch this video to learn about a patient’s experience with STELARA®.
© Janssen Biotech, Inc. 2022 09/22 cp-332748v1
First 52 weeks of therapy
This is dosing information for adults. Find STELARA® dosing information for adolescents.
See how the dosing for STELARA® compares to an oral systemic therapy for the treatment of plaque psoriasis during the first 52 weeks of therapy.
OTEZLA®* (apremilast)
Twice daily after starter dose (dosing milligrams vary during first five days of treatment). Blocks phosphodiesterase 4 (PDE4) enzyme involved in inflammatory and immune responses.
OTEZLA® is indicated for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
*Indicated trademarks are registered trademarks of their respective owners.
‡In medical studies, twice-weekly dosing for ENBREL® was also shown to be effective in the first 12 weeks.
^Based on the recommended 300-mg dose. 150 mg may be acceptable for some patients.
Of all the plaque psoriasis biologic medications, STELARA® has the fewest yearly doses. With only 4 doses a year after 2 starter doses, you have a full 12 weeks between doses.
STELARA® is a 45 mg or 90 mg injection given under the skin, as directed by your doctor. To start, you’ll get doses at weeks 0, 4, and then every 12 weeks after that. Your doctor can administer it, or you (or a caregiver) can inject at your home after proper training. Ask your doctor about which is the right choice for you.
If your doctor decides that you or a caregiver may give your injections at home, you should receive training on the right way to prepare and inject STELARA®. Do not try to inject yourself until you or your caregiver has been properly trained by a healthcare provider.
Please read the Instructions for Use and Medication Guide before using STELARA®.
While the factors represented in the above chart are important, there are additional considerations for selecting treatment. Please talk to your doctor about treatment options and what might be right for you.
The above chart is not intended to compare the safety and effectiveness of these treatments. Please refer to each product’s full Prescribing Information for recommended dosing and administration.
No footer links content fetched